ONPH OTC
Oncology Pharma Inc.
1W: -25.0%
1M: -55.8%
3M: -40.2%
YTD: +650.0%
1Y: +5900.0%
3Y: -91.7%
5Y: -99.9%
$0.03
-0.01 (-32.28%)
Weekly Expected Move ±55.2%
$-0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+100.0% ▲
Operating Income
-$62K
+99.6% ▲
Net Income
-$105M
-7.3% ▼
EPS (Diluted)
$-3.42
+49.4% ▲
EBITDA
$229K
+99.9% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2004 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1M | $0 | $0 | $0 | $0 |
| YoY Growth | -64.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $654K | $1K | $1K | $779 | $0 |
| Gross Profit | $527K | -$1K | -$1K | -$779 | $0 |
| Gross Margin | 44.6% | — | — | — | — |
| R&D Expenses | $376K | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2M | $818K | $403K | $14M | $62K |
| Operating Expenses | $2M | $818K | $403K | $14M | $62K |
| Operating Income | -$2M | -$819K | -$404K | -$14M | -$62K |
| Operating Margin | -144.0% | — | — | — | — |
| Interest Expense | $0 | $32K | $25K | $83M | $105M |
| Income Before Tax | -$2M | -$850K | -$208K | -$97M | -$105M |
| Tax Expense | -$136K | $0 | $0 | $3K | $0 |
| Net Income | -$2M | -$850K | -$208K | -$97M | -$105M |
| Net Margin | -132.5% | — | — | — | — |
| EPS (Diluted) | $-782500.00 | $-0.72 | $-0.12 | $-6.76 | $-3.42 |
| EBITDA | -$2M | -$818K | -$181K | -$15M | $229K |
| Shares Outstanding | 2 | 1M | 2M | 14M | 31M |